XML 115 R60.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Loss Per Common Share (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Numerator - basic:                      
Net loss attributable to Merrimack Pharmaceuticals, Inc. $ (24,768) $ (23,199) $ (20,026) $ (23,284) $ (18,116) $ (18,599) $ (29,051) $ (13,457) $ (91,277) $ (79,223) $ (50,104)
Plus: Unaccreted dividends on convertible preferred stock                 (2,107) (7,789) (11,185)
Net loss available to common stockholders - basic                 (93,384) (87,012) (61,289)
Numerator - diluted:                      
Net loss attributable to Merrimack Pharmaceuticals, Inc. (24,768) (23,199) (20,026) (23,284) (18,116) (18,599) (29,051) (13,457) (91,277) (79,223) (50,104)
Plus: Unaccreted dividends on convertible preferred stock                 (2,107) (7,789) (11,185)
Net loss available to common stockholders - diluted                 $ (93,384) $ (87,012) $ (61,289)
Denominator:                      
Weighted-average common shares-basic and diluted                 72,831 11,343 10,994
Net loss per share available to common stock holders-basic and diluted (in dollar per share) $ (0.26) $ (0.25) $ (0.22) $ (2.14) $ (1.76) $ (1.81) $ (2.76) $ (1.34) $ (1.28) $ (7.67) $ (5.57)
Convertible preferred stock
                     
Potentially dilutive securities excluded from computation of diluted weighted average shares                      
Potentially dilutive securities (in shares)                   66,256 55,253
Options to purchase common stock
                     
Potentially dilutive securities excluded from computation of diluted weighted average shares                      
Potentially dilutive securities (in shares)                 18,066 17,617 16,214
Convertible preferred stock warrants
                     
Potentially dilutive securities excluded from computation of diluted weighted average shares                      
Potentially dilutive securities (in shares)                   302 306
Common stock warrants
                     
Potentially dilutive securities excluded from computation of diluted weighted average shares                      
Potentially dilutive securities (in shares)                 2,842 2,640 2,937